Age-Related Macular Degeneration Clinical Trial
Official title:
Near Visual Acuity and Quality of Life Improvement After Implantation of the add-on Scharioth Macula Lens (SML, Medicontur) in Patients With Dry Age-related Macular Degeneration and Myopic Maculopathy
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in
developed countries among people over 50 years of age. Myopic maculopathy is also an
important cause of irreversible vision loss. Reduced near visual acuity is still a major
problem with all forms of AMD and myopic maculopathy. Various intraocular lenses for near
vision (IOLs) or telescopic systems have been described but are not widely accepted and
almost all solutions require phakic status of the eye and are implanted during cataract
surgery. Therefore, these devices are not appropriated for pseudophakic AMD and myopic
maculopathy patients. Scharioth Macula Lens (SML, Medicontur) is a magnifying intraocular
lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient.
The implant has a bifocal optic, with a central 1.5mm diameter optical zone equivalent to
+10D add and a peripheral zone optically neutral. The implantation of the add-on SML can
improve the near visual acuity of pseudophakic patients with AMD and myopic maculopathy
without impairing their distance visual acuity.
The principal objective is to compare the near visual acuity, the far visual acuity and the
self-reported vision health status before and after the SML implantation.
We present a prospective study of a cohort of patients with age-related macular degeneration
and myopic maculopathy treated with SML implantation. The study was approved by the ethics
committee at the Consorci Sanitari de Terassa (Barcelona, Spain).
Patients will be examined for best corrected visual acuity prior to the surgery at 6 meter
and for reading at 40cm (with a +2.5D) and 15 cm (with +6D). Improvement of the reading
ability at 15 cm compared to 40 cm will predict the potential for vision improvement with the
add on lens.
The preoperative and postoperative assessment will include a full ophthalmological exam,
visual acuity for distance and near, optical coherence tomography of the anterior chamber and
of the macula, axial length and keratometry examination using biometry and VFQ25
questionnaire.
Postoperative assessment will be performed at day 1, 1 week, 1, 3 and 6 months after surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05984927 -
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT04005352 -
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
|
Phase 3 | |
Withdrawn |
NCT02873351 -
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
|
Phase 2 | |
Active, not recruiting |
NCT02802657 -
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
|
Phase 4 | |
Not yet recruiting |
NCT02864472 -
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
|
Phase 4 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02035722 -
Intravitreal Injections-related Anxiety
|
Phase 2/Phase 3 | |
Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01048476 -
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01174407 -
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
|
N/A | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00345176 -
Age-Related Eye Disease Study 2 (AREDS2)
|
Phase 3 | |
Completed |
NCT02140151 -
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02555306 -
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT03166202 -
Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
|
||
Completed |
NCT01397409 -
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
|
Phase 2 |